ESR1 and breast carcinoma: To begin to explore this in the context of ER+/Her2+ breast cancer, BT474 and MDAMB361 cells were grown in 2D monolayers or 3D cultures and exposed to a range of concentrations of tamoxifen, fulvestrant or trastuzumab for 7 days after which cell numbers were counted.